Hematopoietic stem cell transplantation from HLA fully mismatched family members for post-transplant relapse/rejection (phase I/II trial)
Phase 1
Recruiting
- Conditions
- hematologic malignancies relapesd/rejected after allogeneic stem cell transplantation
- Registration Number
- JPRN-UMIN000023548
- Lead Sponsor
- Hyogo College of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1) Cre > 2.0 mg/dl 2) EF < 40% 3) T-Bil > 2.0 mg/dl 4) AST and/or ALT > 200 U/L 5) SpO2 < 90% (room air) 6) PS (ECOG score) 3-4 Patients with data due to original disease are not excluded.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie HLA mismatched hematopoietic stem cell transplantation for post-transplant relapse in hematologic malignancies?
How does HLA fully mismatched hematopoietic stem cell transplantation compare to standard HLA-matched transplants in treating post-transplant relapse/rejection?
What biomarkers are associated with successful engraftment and reduced graft-versus-host disease in HLA fully mismatched hematopoietic stem cell transplantation?
What are the potential adverse events and management strategies for HLA fully mismatched hematopoietic stem cell transplantation in patients with hematologic malignancies?
Are there any combination therapies or alternative approaches being explored alongside HLA fully mismatched hematopoietic stem cell transplantation for post-transplant relapse in hematologic malignancies?